VDA-1102 ointment is the FIRST in a new class of drugs that selectively targets malignant skin cancer cells with minimal effects on surrounding healthy skin.
HK2 has a vital role in cancer metabolism. Vidac is creating innovative therapies for people suffering from a range of oncology and dermatology ailments.